Price data is not available
Polaryx Therapeutics Inc
PLYXNASDAQ
Polaryx Therapeutics fell 94.4% from $35.00 to $1.95, behind the S&P 500's +9.3%. Its worst day was Feb 6 (−45.2%), and its low came Nov 3 at $1.73.
Feb 2, 2026 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Polaryx Therapeutics shares fell 45.2%, while the S&P 500 rose 1.9%.
−45.2%, the year's worst day · S&P 500 +1.9%
Polaryx Therapeutics (NASDAQ: PLYX) shares rise on selecting research organization for SOTERIA trial to evaluate lead candidate for lysosomal storage disorders.
Story events cover the past 12 months · Times ET
+64.3%, on 55M shares, the year's heaviest volume · S&P 500 +0.2%
Polaryx Therapeutics shares rose 69.6%, while the S&P 500 fell 0.2%.
+69.6%, the year's best day · S&P 500 −0.2%
EPS of $-0.05 missed the $-0.02 estimate on $0.00 revenue.
−21.7% · S&P 500 −1.2%
EPS of $-0.03 beat the $-0.04 estimate on $0.00 revenue.
+4.0% · S&P 500 −0.2%
Polaryx Therapeutics closed at its lowest level of the year, 95.1% below where the year started.
−1.1% · S&P 500 +0.3%
Where it ended: a close of $1.95 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 23, 2026 (EPS est. $-0.05).
Nothing in the past 12 months.
All PLYX dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PLYX and SPY from Benzinga historical bars. Not investment advice.
